Aclarion and Weill Cornell Launch Second Spine Trial with Nociscan

Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company specializing in its Nociscan® platform, has announced a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a groundbreaking trial led by renowned neurosurgeon Roger Härtl, MD. The trial, titled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial,” aims to evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate (BMAC) injection on patient outcomes, intervertebral disc health, and pain biomarkers over two years. This research seeks to deepen understanding of degenerative disc disease (DDD) and inform its treatments.

Aclarion’s Nociscan solution is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. It uses magnetic resonance spectroscopy (MRS) data and proprietary AI algorithms to quantify chemical biomarkers associated with disc pain. Aclarion’s Chief Strategy Officer, Ryan Bond, emphasized the significance of this progressive trial, stating that it investigates a major global health issue while using innovative tools like Nociscan. With approximately 266 million people worldwide suffering from degenerative spine disease and chronic low back pain, Nociscan offers critical insights into pain location and has demonstrated a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated.

This partnership marks a pivotal step in advancing spine care. Dr. Härtl highlighted the scientific interest in less invasive surgical and biological treatment strategies for degenerative diseases of the spine. The trial aims to illuminate chemical aspects of disc degeneration not available with traditional imaging. Aclarion’s technology is poised to transform treatment strategies for chronic low back pain, offering hope to millions. For more information, visit Latest News and find a Nociscan center here.